Mark J. Ratain, MD, and Daniel Goldstein, MD, on Value in Cancer Care: How the Paradigm Is Shifting

First International Summit on Interventional Pharmacoeconomics

Mark J. Ratain, MD, of the University of Chicago, and Daniel Goldstein, MD, of the Rabin Medical Center, discuss the challenges of achieving cancer care value, evolution of the “more-is-better” philosophy when it comes to oncology drugs, and highlights of the First International Summit on Interventional Pharmacoeconomics.

Mark J. Ratain, MD, and Daniel Goldstein, MD, on Value in Cancer Care: How the Paradigm Is Shifting

Related Videos

Matthew Seymour, MD: A Clinical Trialist’s Perspective

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

David A. Hyman, MD, JD, on Inclusive Shared Savings

The Interventional Pharmacoeconomic Toolbox Panel Discussion

How Medicare Advantage and Traditional Medicare Influence Palliative and Hospice Care Implementation

Tarlatamab Plus Durvalumab as First-Line Maintenance in Extensive-Stage SCLC

TALENT Neoadjuvant T-DXd in HER2-Low Early Breast Cancer

Adding a Chatbot to Cancer Predisposition Visits Improves Risk Knowledge in AYAs

Substudy Validates Perioperative Approach of Systemic Therapy With Radical Prostatectomy